OpenURL Connection Search

Select item for more details and to access through your institution.

Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.
Published in:
Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-54117-6
By:
- Jørgensen, S. F.;
- Macpherson, M. E.;
- Bjørnetrø, T.;
- Holm, K.;
- Kummen, M.;
- Rashidi, A.;
- Michelsen, A. E.;
- Lekva, T.;
- Halvorsen, B.;
- Trøseid, M.;
- Mollnes, T. E.;
- Berge, R. K.;
- Yndestad, A.;
- Ueland, T.;
- Karlsen, T. H.;
- Aukrust, P.;
- Hov, J. R.;
- Fevang, B.
Publication type:
Article
Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.
Published in:
Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-35367-7
By:
- Jørgensen, S. F.;
- Macpherson, M. E.;
- Bjørnetrø, T.;
- Holm, K.;
- Kummen, M.;
- Rashidi, A.;
- Michelsen, A. E.;
- Lekva, T.;
- Halvorsen, B.;
- Trøseid, M.;
- Mollnes, T. E.;
- Berge, R. K.;
- Yndestad, A.;
- Ueland, T.;
- Karlsen, T. H.;
- Aukrust, P.;
- Hov, J. R.;
- Fevang, B.
Publication type:
Article
Health benefits and risks during 10 years after Roux-en-Y gastric bypass.
Published in:
Surgical Endoscopy & Other Interventional Techniques, 2020, v. 34, n. 12, p. 5368, doi. 10.1007/s00464-019-07328-2
By:
- Chahal-Kummen, M.;
- Salte, O. B. K.;
- Hewitt, S.;
- Blom-Høgestøl, I. K.;
- Risstad, H.;
- Kristinsson, J.;
- Mala, T.
Publication type:
Article

Found: 3

Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Health benefits and risks during 10 years after Roux-en-Y gastric bypass.